Literature DB >> 18474742

Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease.

Beth Kuczynski1, Bruce Reed, Dan Mungas, Michael Weiner, Helena C Chui, William Jagust.   

Abstract

BACKGROUND: Alzheimer disease and cerebrovascular disease affect elderly persons through alterations in brain structure and metabolism that produce cognitive decline. Understanding how each disease contributes to dementia is essential from both a pathophysiologic and diagnostic perspective.
OBJECTIVE: To elucidate how baseline cognitive function (episodic memory and executive function) and brain anatomy (white matter hyperintensities and hippocampal volume) are associated with baseline (positron emission tomography-1 [PET1]) and longitudinal (PET2) glucose metabolism in 38 subjects older than 55 years ranging from normal cognition, cognitive impairment without dementia, and dementia.
DESIGN: Cross-sectional regression analyses across subjects.
SETTING: Multicenter, university-based study of subcortical vascular dementia. MAIN OUTCOME MEASURES: Regional cerebral glucose metabolism was the primary outcome, with the major hypotheses that memory and hippocampal volume are related to temporoparietal hypometabolism while executive function and white matter hyperintensities correlate with frontal lobe hypometabolism.
RESULTS: Low baseline hippocampal volume predicted longitudinal development (PET2) of medial temporal hypometabolism. Lower memory was associated with parietal and cingulate hypometabolism at PET1, which increased at the 2-year-follow-up (PET2). Executive function was associated with frontal and temporoparietal hypometabolism at PET1 but only with frontal hypometabolism at follow-up. White matter hyperintensities predicted hypometabolism over time in the frontoparietal regions, predicting a rate of metabolic change (PET1 - PET2/time).
CONCLUSIONS: Low baseline episodic memory and hippocampal volume predict the metabolic alterations associated with Alzheimer disease, whereas elevated baseline white matter hyperintensities predict a different pattern of metabolic decline that is plausibly associated with cerebrovascular disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474742      PMCID: PMC2556212          DOI: 10.1001/archneur.65.5.650

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  14 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findings.

Authors:  David L Sultzer; Stephen T Chen; Charles V Brown; Michael E Mahler; Jeffrey L Cummings; Charles H Hinkin; Mark A Mandelkern
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2002       Impact factor: 2.198

3.  Automated template-based PET region of interest analyses in the aging brain.

Authors:  Felice T Sun; Roberta A Schriber; Joel M Greenia; Jiawei He; Amy Gitcho; William J Jagust
Journal:  Neuroimage       Date:  2006-11-16       Impact factor: 6.556

4.  Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability.

Authors:  H C Chui; W Mack; J E Jackson; D Mungas; B R Reed; J Tinklenberg; F L Chang; K Skinner; C Tasaki; W J Jagust
Journal:  Arch Neurol       Date:  2000-02

Review 5.  Public health importance of vascular dementia and Alzheimer's disease with cerebrovascular disease.

Authors:  D Bennett
Journal:  Int J Clin Pract Suppl       Date:  2001-05

6.  Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia.

Authors:  Yuan-Yu Hsu; Norbert Schuff; An-Tao Du; Kevin Mark; Xiaoping Zhu; Dawn Hardin; Michael W Weiner
Journal:  J Magn Reson Imaging       Date:  2002-09       Impact factor: 4.813

7.  Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.

Authors:  G McKhann; D Drachman; M Folstein; R Katzman; D Price; E M Stadlan
Journal:  Neurology       Date:  1984-07       Impact factor: 9.910

8.  Effects of subcortical ischemic vascular dementia and AD on entorhinal cortex and hippocampus.

Authors:  A T Du; N Schuff; M P Laakso; X P Zhu; W J Jagust; K Yaffe; J H Kramer; B L Miller; B R Reed; D Norman; H C Chui; M W Weiner
Journal:  Neurology       Date:  2002-06-11       Impact factor: 9.910

9.  Correction of PET data for partial volume effects in human cerebral cortex by MR imaging.

Authors:  C C Meltzer; J P Leal; H S Mayberg; H N Wagner; J J Frost
Journal:  J Comput Assist Tomogr       Date:  1990 Jul-Aug       Impact factor: 1.826

10.  Psychometrically matched measures of global cognition, memory, and executive function for assessment of cognitive decline in older persons.

Authors:  Dan Mungas; Bruce R Reed; Joel H Kramer
Journal:  Neuropsychology       Date:  2003-07       Impact factor: 3.295

View more
  18 in total

1.  Effects of acupuncture on glycometabolic enzymes in multi-infarct dementia rats.

Authors:  Lan Zhao; Peng Shen; Yingying Han; Xuezhu Zhang; Kun Nie; Haiyan Cheng; Bohong Kan; Guomin Li; Jianchun Yu; Jingxian Han
Journal:  Neurochem Res       Date:  2011-01-30       Impact factor: 3.996

Review 2.  Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Authors:  Peter J Nestor; Daniele Altomare; Cristina Festari; Alexander Drzezga; Jasmine Rivolta; Zuzana Walker; Femke Bouwman; Stefania Orini; Ian Law; Federica Agosta; Javier Arbizu; Marina Boccardi; Flavio Nobili; Giovanni Battista Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

3.  Neuropathological associates of multiple cognitive functions in two community-based cohorts of older adults.

Authors:  N Maritza Dowling; Sarah Tomaszewski Farias; Bruce R Reed; Joshua A Sonnen; Milton E Strauss; Julie A Schneider; David A Bennett; Dan Mungas
Journal:  J Int Neuropsychol Soc       Date:  2011-07       Impact factor: 2.892

4.  An inverse association of cardiovascular risk and frontal lobe glucose metabolism.

Authors:  B Kuczynski; W Jagust; H C Chui; B Reed
Journal:  Neurology       Date:  2009-02-24       Impact factor: 9.910

5.  Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Natalia Zarzhevsky; Robert A Koeppe; Christopher W Bogan; Michael R Kilbourn; Kirk A Frey; Roger L Albin
Journal:  Brain       Date:  2011-06-08       Impact factor: 13.501

6.  Increased inhibition and enhancement of memory retrieval are associated with reduced hippocampal volume.

Authors:  B E Depue; M T Banich
Journal:  Hippocampus       Date:  2011-06-08       Impact factor: 3.899

7.  Allopregnanolone Promotes Neuronal and Oligodendrocyte Differentiation In Vitro and In Vivo: Therapeutic Implication for Alzheimer's Disease.

Authors:  Shuhua Chen; Tian Wang; Jia Yao; Roberta Diaz Brinton
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

8.  Relationships between cognitive impairment on ADAS-cog and regional cerebral blood flow using SPECT in late-onset Alzheimer's disease.

Authors:  Michio Takahashi; Yasunori Oda; Toshiyuki Okubo; Yukihiko Shirayama
Journal:  J Neural Transm (Vienna)       Date:  2017-05-16       Impact factor: 3.575

9.  Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions.

Authors:  Larry G Brooks; David A Loewenstein
Journal:  Alzheimers Res Ther       Date:  2010-09-29       Impact factor: 6.982

10.  Reduced glucose uptake and Aβ in brain regions with hyperintensities in connected white matter.

Authors:  L Glodzik; A Kuceyeski; H Rusinek; W Tsui; L Mosconi; Y Li; R S Osorio; S Williams; C Randall; N Spector; P McHugh; J Murray; E Pirraglia; S Vallabhajosula; A Raj; M J de Leon
Journal:  Neuroimage       Date:  2014-07-04       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.